Harbinger Health has raised $140m in a Series B funding round, which will enable the completion of the study of its first blood-based screening product for cancer.

The funding round consists of the company’s founder, Flagship Pioneering, and various global institutional investors, including Pictet, Partners Investment and M&G.

Harbinger will use this financing to complete the Cancer ORigin Epigenetics-Harbinger Health clinical study of its new cancer screening platform, HarbingerHx, involving 10,000 participants.

HarbingerHx uses machine learning and growing datasets for developing insights that increase clinical informativeness.

The company will also expand its teams, develop its two-tier testing model and commence additional trials in high-risk populations using the funding.

Harbinger’s two-tier testing model is being developed to make cancer screening more accessible worldwide.

Harbinger Health CEO Stephen Hahn said: “At Harbinger, our goal is to lead the way to a future where cancer screening is routine, affordable and accessible for everyone.

“We have a unique opportunity to make cancer screening tools work better and work for more people through our biological and technical solutions.

“We are achieving this by combining machine learning with insights into the biology of cancer’s origins and individual risk in order to provide actionable information to providers, enabling them to guide improved clinical decision-making for their patients.”

The company plans to launch its first laboratory-developed test product in 2025 and expects to create more tests for different types of cancer and groups of people in the future.

Since its inception in 2020, Harbinger has raised nearly $190m in total funding.